Psychedelics healthcare company Numinus Wellness (OTCQX:NUMIF) shared its unaudited, condensed and consolidated interim financial results for the three and six months ended February 29, 2024.

Q2 showed:

Cash position of $4.8 (CA$6.6) million by February 29, 2024, compared to the $14.33 million held by February 28, 2023. Three and six months revenue of $3.66 million and $7.98 million respectively, compared to $3.89 million and $8.0 million during the same comparable periods in 2023. After costs, three and six months gross profit was $1.2 million and $2.77 million respectively, while $1.53 million and $3.26 million during the same periods in 2023. Three and six months G&A (general and administrative) expenses totaled $4.23 million and $8.16 million, as compared to...